Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expert view: Chinese healthcare industry entering a 'new normal'?

This article was originally published in Scrip

Executive Summary

Two years after the GSK scandal broke in China, a national campaign against corruption is marching on in the country, and a series of recent events suggests that Chinese authorities are determined to clean up the healthcare industry and bring in a 'new normal'. For multinational companies, the shakeup should come as welcome news, and it is time to devise strategies to prepare for a new phase of reform in the country, writes Pengfei Lu, director of corporate strategy at the research services company Wuxi AppTec.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts